HYDROCORTISONE JUNO (Juno Pharmaceuticals Pty Ltd)

1. Endocrine Disorders

• Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogues may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplements may be necessary, particularly when synthetic analogues are used).
• Preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful
• Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected
• Congenital adrenal hyperplasia
• Nonsuppurative thyroiditis
• Hypercalcaemia associated with cancer.

2. Rheumatic Disorders

As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:

• Post-traumatic osteoarthritis
• Synovitis of osteoarthritis
• Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy)
• Acute and subacute bursitis
• Epicondylitis
• Acute nonspecific tenosynovitis
• Acute gouty arthritis
• Psoriatic arthritis
• Ankylosing spondylitis.

3. Collagen Diseases

During an exacerbation or as maintenance therapy in selected cases of:

• Systemic lupus erythematosus
• Systemic dermatomyositis (polymyositis) Acute rheumatic carditis.

4. Dermatological Diseases

• Pemphigus
• Severe erythema multiforme (Stevens-Johnson Syndrome)
• Exfoliative dermatitis
• Bullous dermatitis herpetiformis
• Severe seborrhoeic dermatitis
• Severe psoriasis
• Mycosis fungoides.

5. Allergic States

Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in:

• Bronchial asthma
• Drug hypersensitivity reactions
• Contact dermatitis
• Urticarial transfusion reactions
• Atopic dermatitis
• Serum sickness
• Acute noninfectious laryngeal oedema (adrenaline is the drug of first choice).

6. Ophthalmic Diseases

Severe acute and chronic allergic and inflammatory processes involving the eye, such as:

• Herpes zoster ophthalmicus
• Iritis, iridocyclitis
• Chorioretinitis
• Diffuse posterior uveitis and choroiditis
• Optic neuritis
• Sympathetic ophthalmia
• Anterior segment inflammation
• Allergic conjunctivitis
• Allergic corneal marginal ulcers
• Keratitis.

7. Gastrointestinal Diseases

To tide the patient over a critical period of the disease in:

• Ulcerative colitis (systemic therapy)
• Regional enteritis (systemic therapy).

8. Respiratory Diseases

• Symptomatic sarcoidosis
• Loeffler’s Syndrome not manageable by other means
• Berylliosis
• Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy
• Aspiration pneumonitis.

9. Haematological Disorders

• Acquired (autoimmune) haemolytic anaemia
• Erythroblastopenia (RBC anaemia)
• Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated)
• Secondary thrombocytopenia in adults
• Congenital (erythroid) hypoplastic anaemia.

10. Neoplastic Diseases

For palliative management of:

• Leukaemias and lymphomas in adults
• Acute leukaemia in childhood.

11. Oedematous States

• To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uraemia, of the idiopathic type or that due to lupus erythematosus.

12. Miscellaneous

• Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy
• Trichinosis with neurological or myocardial involvement.